Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul>
<li>Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.</li>
<li>The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.</li>
<li>This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.</li>
</ul>


Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.
The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.
This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.


Light Science Technologies Holdings (LST LN)

Arecor Therapeutics

Hybridan Small Cap Feast: 13 August 2026